secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-041385
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest Q2 2023 net loss $7.6M; TPST-1120 HCC data shows 74% ORR improvement over control
--------------------------------------------------------------------------------

- Cash $17.6M at June 30, 2023, down from $31.2M at Dec 31, 2022.
- Net loss Q2 2023 $7.6M ($0.54/share) vs $9.2M ($0.79/share) in Q2 2022.
- TPST-1120 in first-line HCC: unconfirmed ORR 30% (12/40) vs 17.2% (5/29) for control; confirmed ORR 17.5% vs 10.3%.
- 47.5% of TPST-1120 arm patients on treatment vs 23.3% in control; 80% on study vs 50%.
- Expect to discuss updated TPST-1120 data from formal review in H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000095017023041385/0000950170-23-041385-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000095017023041385/tpst-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041385

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer